Clinical trials: Immunotoxicity
SARS-CoV-2, Safety
The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
This study plans to enrol 1000 participants 18 years and above, with ≥10% participants ≥60 years old. According to SARS-CoV-2 vaccine vaccination history, they will be evenly divided into 2 groups, Group A and Group B.
- Conditions
- SARS-CoV-2, Safety, Immunotoxicity
- Trial name
- NCT05492643
- Testing
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity, Humoral Immunity
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Immunotoxicity, Anesthesia
Anesthetic Depth Effects Upon Immune Competent Cells
Anesthesia depth affects the proliferation of lymphocytes to NK-cells and memory T-cells effect and the phagocytosis activity of macrophages in healthy patients.
- Conditions
- Immunotoxicity, Anesthesia, Inert Gas Narcosis
- Trial name
- BIS-MA (NCT02794896)
- Testing
- High dose propofol, fentanyl and sevoflurane, Low dose propofol, fentanyl and sevoflurane
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Heidelberg University
Cytokine Release Syndrome
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS).
- Trial name
- NCT05905328
- Testing
- CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- CytoAgents, Inc.
Autoimmunity, Cancer
Autoimmunity After Checkpoint Blockade
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity.
- Conditions
- Autoimmunity, Cancer, Immunotoxicity, Oncology
- Trial name
- NCT04119713
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Immunotoxicity, Vaccine
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.
- Trial name
- NCT05161845
- Testing
- Measles, Mumps and Rubella Combined Vaccine, Live
- Where
- China
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Skin Toxicity, Immunotoxicity
Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities
Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications.
- Trial name
- ImmunoSkin (NCT04929834)
- Testing
- Hydrating emollient + body lotion for immunotherapy-related side effects
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Jessa Hospital
Melanoma, Immunotoxicity
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Management of melanoma is based on primary excision of the tumor. In cases of melanoma with poor prognosis criteria, or when it is locally advanced or metastatic, there is an indication for the implementation of adjuvant therapy…
- Trial name
- APiTOXMM (NCT06627595)
- Testing
- Immunotherapy
- Where
- 2 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier